DKK1 and gastric cancer: Recently, the anti-DKK1 neutralizing antibody DKN-01, which is developed by Leap Therapeutics, are being evaluated in phase I or phase II trials of advanced gastroesophageal junction and gastric cancer (GEJ/GC) and gynecologic cancers, in the form of both monotherapy and combination therapy with paclitaxel or pembrolizumab.